



CIN NO.: L24230WB1982PLC034492

26<sup>th</sup> May, 2017

To,  
The Secretary,  
**The Calcutta Stock Exchange Limited**  
7, Lyons Range,  
Kolkata – 700 001

To,  
Dy. General Manager,  
Corporate Relationship Department,  
**BSE Limited,**  
P. J. Tower,  
Mumbai – 400 001

**SUB: Submission of Audited Financial Results for the 04<sup>th</sup> Quarter and year ended 31<sup>st</sup> March, 2017 pursuant to Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015**

Dear Sir,

Pursuant to Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that the Meeting of Board of Directors of the Company held at its Registered Office on Friday, 26<sup>th</sup> May, 2017 (which commenced at 5.00 P.M. and concluded 8.25 P.M.) wherein they have adopted / approved:

- 1) The Audited Standalone Financial Results of the Company for the 4<sup>th</sup> quarter and Year ended 31/03/2017 along with the Statement of Assets and Liabilities.
- 2) Statement on Impact of Audit Qualifications (for Audit Report with unmodified opinion)
- 3) Auditor's Report on the Annual Audited Standalone Financial Results.
- 4) Declaration by Whole-time Director pursuant to Regulation 33 (3) (d) of the SEBI (LODR) Regulation, 2016.

The said results will be duly published in the newspapers within due course of time.


The above information is also available on Company's website [www.adinathbio.com](http://www.adinathbio.com) and on the Stock exchange website: [www.bseindia.com](http://www.bseindia.com) and [www.cse-india.com](http://www.cse-india.com).

Request you to kindly take the above on record.

Thanking you,

Yours faithfully,

**For Adinath Bio-Labs Limited**

  
**Abhishek Kumar Jain**  
(Whole-Time Director)  
DIN: 00054582




Encl.: As above

Email: [investors@adinathbio.com](mailto:investors@adinathbio.com)  
<http://www.adinathbio.com>

4, N. S. Road, 1<sup>st</sup> Floor, Kolkata – 700 001  
Telephone: +91-33-22315718

ADINATH BIO-LABS LIMITED						
CIN: L24230WB1982PLC034492						
Statement of Standalone Audited Financial Results for the 4th Quarter and Year Ended 31st March, 2017						
PART I					(Rs. in Lakhs)	
Sr. No.	Particulars	3 months ended (31/03/2017)	Preceding 3 months ended (31/12/2016)	Corresponding 3 months ended (31/03/2016) in the previous year	Year to date figures for current period ended (31/03/2017)	Year to date figures for previous year ended (31/03/2016)
		Audited	Unaudited	Audited	Audited	Audited
I	Revenue from operations	9.67	11.44	18.70	55.82	80.53
II	Other Income	0.18	-	0.00	0.18	19.19
III	Total Revenue(I+II)	9.85	11.44	18.70	56.00	99.72
IV	Expenses					
	(a) Cost of materials consumed	-	-	-	-	-
	(b) Purchases of stock-in-trade	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock- in-trade	-	-	-	-	-
	(d) Employee benefits expense	2.32	3.87	5.41	18.07	19.86
	(e) Finance Cost	-	-	-	-	-
	(f) Depreciation and amortisation expense	2.86	2.86	4.06	11.45	16.08
	(g) Other expenses	4.43	4.17	8.17	23.51	33.42
	Total expenses	9.61	10.90	17.64	53.04	69.36
V	Profit before exceptional and extraordinary items and tax(III-IV)	0.24	0.54	1.06	2.96	30.36
VI	Exceptional items	-	-	-	-	-
VII	Profit before extraordinary items and tax (V +/- VI)	0.24	0.54	1.06	2.96	30.36
VIII	Extraordinary items	-	-	-	-	-
IX	Profit before tax (VII+/- VIII)	0.24	0.54	1.06	2.96	30.36
X	Tax expense					
	(1)Current Tax	-	-	-	0.98	7.86
	(2)Deferred Tax	-	-	-	(0.09)	(0.74)
	(3)Tax in respect of earlier years	-	-	-	-	8.87
XI	Profit (Loss) for the period from continuing operations (IX-X)	0.24	0.54	1.06	2.07	14.37
XII	Profit/(loss) from discontinuing operations	-	-	-	-	-
XIII	Tax expense of discontinuing operations	-	-	-	-	-
XIV	Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)	-	-	-	-	-
XV	Profit (Loss) for the period (XI+/-XIV)	0.24	0.54	1.06	2.07	14.37
XVI	Earnings Per Share (Equity Share of Rs. 1/- each) (not annualised)					
	(a) Basic	0.00	0.00	0.00	0.00	0.01
	(b) Diluted	0.00	0.00	0.00	0.00	0.01



<b>ADINATH BIO-LABS LIMITED</b>		
<b>Statement of Assets and Liabilities as at 31st March, 2017</b>		
<b>(Rs. in Lakhs)</b>		
<b>Standalone Statement of Assets and Liabilities</b>	<b>As on 31-03-2017</b>	<b>As on 31-03-2016</b>
<b>Particulars</b>	<b>Audited</b>	<b>Audited</b>
<b>A EQUITY AND LIABILITIES</b>		
<b>1 Shareholders' funds</b>		
(a) Share capital	2,207.43	2,207.43
(b) Reserves and surplus	724.69	722.61
<b>Sub-total - Shareholders' funds</b>	<b>2,932.11</b>	<b>2,930.04</b>
<b>2 Non-current liabilities</b>		
(a) Deferred Tax Liabilities	1.36	1.46
<b>Sub-total - Non-Current Liabilities</b>	<b>1.36</b>	<b>1.46</b>
<b>3 Current liabilities</b>		
(a) Other Current Liabilities	3.92	5.97
(b) Short-term Provisions	12.64	11.66
<b>Sub-total - Current Liabilities</b>	<b>16.56</b>	<b>17.63</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>2,950.04</b>	<b>2,949.13</b>
<b>B ASSETS</b>		
<b>1 Non-current assets</b>		
(a) Fixed assets		
(i) Tangible Assets	44.19	55.64
(ii) Capital Work IN Progress	186.56	186.56
(b) Non-Current Investments	73.30	55.75
(c) Long-term loans and advances	1,575.45	1,575.44
(d) Other Non Current Assets	1,005.86	1,005.87
<b>Sub-total - Non-current assets</b>	<b>2,885.36</b>	<b>2,879.26</b>
<b>2 Current assets</b>		
(a) Trade Receivables	62.04	62.04
(b) Cash and cash equivalents	2.64	7.83
<b>Sub-total - Current assets</b>	<b>64.68</b>	<b>69.87</b>
<b>TOTAL - ASSETS</b>	<b>2,950.04</b>	<b>2,949.13</b>





CIN NO.: L24230WB1982PLC034492

**Notes:**

1. The above Financial results have been reviewed by the Audit committee held on 25<sup>th</sup> May, 2017 and adopted by the Board of Directors at their meeting held on 26<sup>th</sup> May, 2017.
2. The results are based on the Standalone financial statements prepared by the Company's management in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Companies Act, 2013 read with relevant rules issued there under. The standalone financial results are made available to the Stock Exchanges where the Company's securities are listed and are posted on the company's website [www.adinathbio.com](http://www.adinathbio.com).
3. There is only one reportable segment i.e. Trading in commodity and it's allied products as envisaged by Accounting Standard 17 'Segment Reporting' prescribed by the Companies (Accounting Standards) Rules, 2006.
4. Provision for taxation is made on the taxable income for the full year in accordance with the provision of Income Tax Act, 1961.
5. Figures of the previous period have been regrouped / rearrange wherever necessary.
6. The figures of last quarter for the standalone account are the balancing figures between the audited figures in respect of the full financial year ended 31<sup>st</sup> March, 2017 and the unaudited published year to date figures upto 31<sup>st</sup> December, 2016 which were subject to limited review.

Place: Kolkata  
Date: 26/05/2017



**By order of the Board  
For Adinath Bio-Labs Limited**

*Abhishek Jain*  
**Abhishek Kumar Jain)**  
**Whole time Director**  
**DIN: 00054582**

**“Statement on Impact of Audit Qualifications”  
(For Audit Report with unmodified opinion)**

**As per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)  
Regulations, 2015**

1.	Name of the company	Adinath Bio-Labs Limited
2.	Annual financial statements for the year ended	31 <sup>st</sup> March 2017 (Standalone)
3.	Type of Audit observation	Un Modified
4.	Frequency of observation	Not Applicable

**For Adinath Bio- Labs Limited**

*Abhishek Jain*

**Abhishek Kumar Jain**  
Whole-Time Director  
DIN: 00054582



**For Mohindra Arora & Co.  
(Chartered Accountants)**

*Ashok Kumar Katial*

**Ashok Kumar Katial**  
Partner  
M. No. 09096



**For Adinath Bio- Labs Limited**

*Chanderkala Devi Lakhotia*

**Chanderkala Devi Lakhotia**  
Director / CFO  
DIN: 06904489



**For Adinath Bio- Labs Limited**

*Manoj Kumar Bothra*

**Manoj Kumar Bothra**  
Audit Committee Chairman  
DIN: 00780987



**Auditor's Report on Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To,  
Board of Directors of  
Adinath Bio-Labs Limited

We have audited the quarterly financial results of Adinath Bio-Labs Limited for the quarter ended 31<sup>st</sup> March, 2017 and the year to date results for the period 01<sup>st</sup> April, 2016 to 31<sup>st</sup> March, 2017 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the related financial statements, which are the responsibility of the company's management and approved by the Board of Directors. Our responsibility is to express an opinion on these financial results based on our audit of such financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

(i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and

(ii) give a true and fair view of the net profit and other financial information for the quarter ended 31<sup>st</sup> March, 2017 as well as the year to date results for the period from 1<sup>st</sup> April, 2016 to 31<sup>st</sup> March, 2017.

For Mohindra Arora & Co.  
Chartered Accountants  
FRN: 006551N



Ashok Kumar Katial  
Partner  
M. No. 09096  
Place: Mumbai  
Date: 25/05/2017





CIN NO.: L24230WB1982PLC034492

## DECLARATION

### Pursuant to Regulation 33 (3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2016

Dear Sir,

I, Mr. Abhishek Kumar Jain (DIN: 00054582) Whole Time Director of Adinath Bio-Labs Limited, hereby declared and confirmed that, the Statutory Auditors of the Company, M/s. Mohindra Arora & Co., Chartered Accountants (FRN: 006551N) have issued an Audit Report with unmodified opinion on Annual Audited Standalone Financial Results for the quarter and year ended 31<sup>st</sup> March, 2017.

This declaration is issued in compliance of Regulation 33(3)(d) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended by the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2016 vide notification No. SEBI/LAD-NRO/GN/2016-17/001 and Circular No. CIR/CFD/CMD/56/2016.

Thanking you,

Yours faithfully,

For Adinath Bio-Labs Limited

*AK Jain*  
**Abhishek Kumar Jain**  
**(Whole-Time Director)**  
**DIN: 00054582**



Date: 26/05/2017  
Place: Kolkata